Entera Bio (STU:5DT) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
26 GF Score
Price €2.44
GF Value €0.21
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Entera Bio Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Entera Bio Quality Rank Related Terms

STU:5DT
26GF Score
Entera Bio Ltd STU:5DT
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Entera Bio (STU:5DT) Overvalued in 2026?

Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued. The current stock price of €2.44 is trading 1061.9% above its estimated GF Value™ of €0.21. GuruFocus considers Entera Bio to be Significantly Overvalued.

Key valuation signals for STU:5DT:

  • Quality Rank:
  • GF Value™: €0.21 vs. price of €2.44 (1061.9% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
26GF Score

Get the complete analysis for STU:5DT

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price
€0.21
GF Value